Company Number: 15003827

Analysis Date: 2025-07-29 13:54 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Clark Pharma Diagnostics Ltd is a newly incorporated company (July 2023) with a limited operating history, which inherently increases credit risk due to lack of proven trading performance. The latest accounts to July 2024 show a modest net asset base (£2,085) and positive working capital (£2,085). However, current liabilities include loans from directors (£1,853) indicating reliance on internal funding. No employees are reported yet, suggesting the business is in startup phase and may have limited cash inflows. Given these factors, credit approval should be conditional on monitoring operating cash flows and securing further financial information as trading progresses.

2. Financial Strength:
   The balance sheet shows a small equity base funded by share capital and retained earnings of approximately £2,085. Current assets consist solely of cash (£10,585), with no fixed or other current assets disclosed, implying minimal asset backing. Current liabilities total £8,500, primarily VAT (£5,215), tax and social security (£1,432), and director loans (£1,853). The net current asset position is positive but narrow, which could constrain liquidity if expenses or liabilities grow. Overall, the company’s financial strength is weak but not critical at this stage due to the small scale and lack of operational history.

3. Cash Flow Assessment:
   Cash on hand of £10,585 versus short-term liabilities of £8,500 provides a minimal liquidity buffer. The company currently has no employees and limited operating activity, which may keep outflows low. However, VAT and tax liabilities suggest some business activity requiring careful management of cash to ensure timely payments. The director loans reflect short-term funding support but may not be sustainable long term. There is no evidence of operational cash inflows yet, so the company's ability to generate positive cash flow must be closely monitored before extending significant credit.

4. Monitoring Points:

• Revenue and cash flow generation in the next 12 months to confirm business viability.
• Changes in working capital, particularly VAT and tax liabilities, which may impact liquidity.
• Director loan balances and any new external financing arrangements.
• Appointment of employees and related payroll obligations.
• Timely filing of future accounts and confirmation statements to maintain regulatory compliance.